Wake Forest Hsp70 research update

The Mulligan Lab is currently completing treatments of the SOD1G93A mouse model of ALS with four different doses of the Hsp70 protein and hopes to have the dose response study complete by the end of March/mid-April. With positive results (hopefully), our ALS scientists and clinicians will begin to design initial clinical trials in patients.

City Bikes IRONMAN® 70.3 Miami

The City Bikes IRONMAN® 70.3 Miami is honored to continue supporting the Blazeman Foundation for ALS. Through this partnership, athletes who are participating in the race have the opportunity to make a contribution to the foundation when registering for the event and support the fight against ALS (Amyotrophic Lateral Sclerosis). The Blazeman Foundation will also be featured at the event EXPO so not only athletes but everyone attending has a chance to know more about the War on ALS.

Brandeis University Research Update

The Rodal lab submitted their first paper describing the Blazeman-funded work a few months ago (to the Journal of Neuroscience), and the peer reviewers were very positive about it. The reviewers asked the lab to do a few more experiments before it can be accepted, and they’re working very hard on completing those. In the meantime, they are also working very hard on a second paper that incorporates work from mammalian neurons. Drs. Deshpande and Rodal were also invited to write a review article summarizing the current status of the field, and how studying transport in neurons has led to increased understanding of neurological disease.